About OsteoStrata
OsteoStrata was created to provide biotechnology and pharmaceutical teams with an alternative to both generalist consulting and fragmented specialist advice.
Our work is dedicated to osteoarthritis, with particular depth in knee osteoarthritis. This focus allows us to integrate scientific, clinical, methodological, regulatory and commercial perspectives while retaining disease-specific expertise.
The name OsteoStrata evokes the stratified complexity of osteoarthritis — the layered biology, phenotypes, endotypes, theratypes, biomarkers and imaging signals that must be integrated to bring clarity to development decisions.
Our principles
We focus on osteoarthritis rather than applying a general development template across unrelated diseases.
Projects are led directly by experienced senior advisers. Strategic thinking is not delegated to an anonymous junior team.
We are not tied to a CRO, imaging provider, laboratory, technology platform or therapeutic modality.
We test assumptions, identify weak evidence and distinguish an attractive narrative from a defensible development hypothesis.
We connect mechanism, patient, biomarker, trial, regulation and value.
We work with commercially sensitive programmes and unpublished evidence under strict confidentiality.
We can remain involved beyond the report — supporting implementation, regulatory meetings, advisory boards and subsequent decisions.
Proprietary knowledge environment
Our work is supported by a continuously developed internal knowledge environment incorporating public evidence, structured pipeline intelligence, trial-design precedents, regulatory learning, expert interpretation and appropriately governed proprietary experience.
Client-confidential information remains segregated and is never transferred across engagements.
Senior advisers
Osteoarthritis biology · Clinical development
Two decades advising biotechnology and pharmaceutical sponsors on knee osteoarthritis programmes — from target validation and translational strategy to Phase II and Phase III trial design. Background spans academic musculoskeletal research, industry clinical development and regulatory interaction with EMA and FDA.
Biomarkers · Imaging · Value strategy
Specialist in evidence architecture for osteoarthritis — biomarker contexts of use, quantitative imaging strategy, estimands, and the translation of clinical evidence into regulatory, partnering and reimbursement value. Prior roles span global pharma medical affairs, biomarker companies and independent advisory.
Specialist judgement at every critical decision.
Speak With a Senior Adviser